Our research group studies the utility of different methods to characterize the chronic and long-term adverse cardiovascular side effects of conventional and novel cancer therapies. By investigating the use of these tools, we can better understand how cancer therapeutics damage organs such as the heart and skeletal muscles, as well as identify those individuals at high risk of cardiovascular side effects. In doing so, we can design therapeutic interventions to prevent and/or mitigate these devastating side effects.

Publications

Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, Tonorezos E, Soares-Miranda L, Sklar CA, Douglas PS, Robison LL, Oeffinger KC. Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study. Journal of Clinical Oncology. 2014, 32:3643-50.

Betof AS, Lascola CD, Fowler E, Scarbrough PM, Jones LW*, Dewhirst MW*. Exercise inhibits tumor progression and sensitizes tumors to chemotherapy in orthotoptic models of breast cancer. Journal of the National Cancer Institute. In Press *co-senior authorship.

Glass OK, Inman BA, Broadwater G, Courneya KS, Mackey JR, Goruk S, Field CJ, Joy AA, Nelson E, Jasper J, Bain JR, Muehlbauer M, Stevens RD, Hirschey MD, Jones LW. Effects of aerobic training on the host systemic milieu in patients with solid tumors and cancer cell phenotype in vitro. British Journal of Cancer. In Press

Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, Whellan DJ, O’Connor CM. Safety and efficacy of aerobic training in patients with cancer who have heart failure: An analysis of the HF-ACTION randomized trial. Journal of Clinical Oncology, 2014; 32:2496-502.

Jones LW, Dewhirst MW. Therapeutic properties of aerobic training after a cancer diagnosis: more than a one trick pony? Journal of the National Cancer Institute, 2014, 106;